Close

Biotech Stocks Technical Report — Research on Exact Sciences, Anacor Pharma, Cubist Pharma, and Agenus

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

The Best Type of Accreditation for a Telehealth Provider

Telehealth and remote patient monitoring services are becoming more...

Pharmaceutical Contract Sales Market to Hit $26.24B by 2034

Contract Sales Organizations: Transforming Pharma Companies Contract sales organizations –...

What Are the Benefits of Outsourcing to a Clinical Research Organization?

Have you ever wondered if outsourcing certain tasks could...

What’s Missing from Drug Warning Labels? A Look at Patient Safety

Drug warning labels are meant to protect patients. But...

On Friday, June 06, 2014, the NASDAQ Composite ended at 4,321.40, up 0.59%, the Dow Jones Industrial Average finished the day 0.52% higher at 16,924.28, and the S&P 500 closed at 1,949.44, up 0.46%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 694.70, down 0.10%, while the index has advanced 3.94% in the last one month. Investor-Edge has initiated coverage on the following equities: Exact Sciences Corp. (NASDAQ: EXAS), Anacor Pharmaceuticals Inc. (NASDAQ: ANAC), Cubist Pharmaceuticals Inc. (NASDAQ: CBST) and Agenus Inc.

On Friday, Exact Sciences Corp.’s stock recorded a trading volume of 1.04 million shares, lower than its three months average volume of 2.28 million shares. The stock finished the day at $15.21, up 0.93%, and registered an intraday range of $14.78 and $15.23. Exact Sciences Corp.’s shares have rallied 11.43% in the previous three trading sessions and 35.20% in the last one month. Also, the stock has gone up 29.45% on YTD basis. Furthermore, the company’s stock is trading above its 50-day and 200-day moving averages. The stock’s 50-day moving average of $12.96 is above its 200-day moving average of $12.53. Additionally, Shares of the company have a Relative Strength Index (RSI) of 69.97.

Anacor Pharmaceuticals Inc.’s stock gained 1.76%, to close Friday’s session at $15.57, after oscillating between $15.01 and $15.59. The stock recorded a trading volume of 0.15 million shares, below its three months average volume of 0.45 million shares. Over the past three trading sessions and last one month, Anacor Pharmaceuticals Inc.’s shares have advanced 9.96% and 2.87%, respectively. However, from the beginning of 2014, the company’s stock has lost 7.21%. The stock is trading above its 200-day moving average. The company stock’s 50-day moving average of $16.06 is above its 200-day moving average of $15.51. Further, the company’s stock has an RSI of 54.14.

On Friday, Cubist Pharmaceuticals Inc.’s stock finished the session 2.01% higher at $70.06. A total of 0.76 million shares were traded, which was below its three months average volume of 0.81 million shares. The stock moved between $68.81 and $71.10 during the session. Over the past three trading sessions and last one month, Cubist Pharmaceuticals Inc.’s shares have surged 5.07% and 4.10%, respectively. Also, the stock has gained 1.73% since the start of this year. The company’s shares are trading above their 50-day and 200-day moving averages. Moreover, the stock’s 200-day moving average of $68.28 is greater than its 50-day moving average of $67.65. Cubist Pharmaceuticals Inc.’s stock traded at a PE ratio of 66.88 and has an RSI of 59.23.

Shares in Agenus Inc. fluctuated between $3.03 and $3.22 before ending Friday’s session up 1.27%, at $3.19. The company’s stock reported a trading volume of 0.27 million shares, below its three months average volume of 0.72 million shares. Further, Agenus Inc.’s shares have gone up 1.59% over the past three trading sessions and 28.11% over the last one month. Also, the stock has surged 20.83% on YTD basis. The stock is trading above its 50-day and 200-day moving averages. The stock’s 200-day moving average of $3.01 is greater than its 50-day moving average of $2.81. Moreover, shares of the company have an RSI of 67.26.

Latest stories

Related stories

The Best Type of Accreditation for a Telehealth Provider

Telehealth and remote patient monitoring services are becoming more...

Pharmaceutical Contract Sales Market to Hit $26.24B by 2034

Contract Sales Organizations: Transforming Pharma Companies Contract sales organizations –...

What Are the Benefits of Outsourcing to a Clinical Research Organization?

Have you ever wondered if outsourcing certain tasks could...

What’s Missing from Drug Warning Labels? A Look at Patient Safety

Drug warning labels are meant to protect patients. But...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back